Glenmark Pharmaceuticals (NSE:GLENMARK) Total Liabilities : ₹65,111 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Glenmark Pharmaceuticals Total Liabilities?

Glenmark Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was ₹65,111 Mil.

Glenmark Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (₹102,707.41 Mil) to Dec. 2023 (₹0.00 Mil) but then increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹65,110.77 Mil).

Glenmark Pharmaceuticals's annual Total Liabilities increased from Mar. 2022 (₹76,451.68 Mil) to Mar. 2023 (₹95,324.17 Mil) but then declined from Mar. 2023 (₹95,324.17 Mil) to Mar. 2024 (₹65,110.77 Mil).

Glenmark Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Glenmark Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glenmark Pharmaceuticals Total Liabilities Chart

Glenmark Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

86,146.94

85,393.04

76,451.68

95,324.17

65,110.77

Glenmark Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															95,324.17	-	102,707.41	-	65,110.77

Glenmark Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Glenmark Pharmaceuticals's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	58185.87	+	(1516.91	+	5407.99
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	65,111

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	143586.24	-	78475.47
	=	65,111

Glenmark Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	58185.87	+	(1516.91	+	5407.99
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	65,111

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	143586.24	-	78475.47
	=	65,111

Glenmark Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Glenmark Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Glenmark Pharmaceuticals (NSE:GLENMARK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Glenmark Pharmaceuticals Ltd (NSE:GLENMARK) » Definitions » Total Liabilities

Traded in Other Exchanges

532296:India

Address

Glenmark House, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri (East), Mumbai, IND, 400099

Website

https://www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.

Glenmark Pharmaceuticals (NSE:GLENMARK) Headlines

No Headlines